Moreover, following vaccination with modified autologous melanoma cells as postsurgical adjuvant therapy, the changes in postvaccination serum CEACAM1 correlate with overall survival and with the S100B melanoma marker [27]. This evidence concerns the gene CEACAM1 and melanoma.